Emergence of targeted molecular imaging in atherosclerotic cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 197-204

  Desai, Milind Y ^a   Schoenhagen, Paul ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Cardiovascular; Coronary artery disease; Macrophage; Molecular imaging

Indexed keywords

CARBON NANOTUBE; CONTRAST MEDIUM; DENDRIMER; FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM; LIPOSOME; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; N 1177; NANOPARTICLE; POLYMER; PROTEINASE; SILICON; TITANIUM DIOXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ZINC OXIDE;

ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DIAGNOSTIC VALUE; DISEASE COURSE; DNA DAMAGE; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; FIBROBLAST; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; KERATINOCYTE; LIPID METABOLISM; MACROPHAGE; MOLECULAR IMAGING; MONOCYTE; MORBIDITY; MORTALITY; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOXICITY TESTING; ANIMAL; DIAGNOSTIC IMAGING; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ENDOTHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPID METABOLISM; NEOVASCULARIZATION, PATHOLOGIC;

EID: 64749084116     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.197     Document Type: Review

References (96)

1. Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 281, 727-735 (1999).
2. Tuzcu EM, Kapadia SR, Tutar E et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103, 2705-2710 (2001).
3. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371-1375 (1987).
4. Schoenhagen P, Ziada KM, Vince DG, Nissen SE, Tuzcu EM. Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J. Am. Coll. Cardiol. 38, 297-306 (2001).
5. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336, 1276-1282 (1997).
6. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 105, 297-303 (2002).
7. Ivan E, Khatri JJ, Johnson C et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation 105, 2686-2691 (2002).
8. Schoenhagen P, Vince DG, Ziada KM et al. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am. J. Cardiol. 89, 1354-1359 (2002).
9. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 101, 598-603 (2000).
10. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 105, 939-943 (2002).
11. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 111, 3481-3488 (2005).
12. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38 (2005).
13. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979 (1997).
15. Asakura M, Ueda Y, Yamaguchi O et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J. Am. Coll. Cardiol. 37, 1284-1288 (2001).
16. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347, 5-12 (2002).
17. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N. Engl. J. Med. 343, 915-922 (2000).
18. Rioufol G, Finet G, Ginon I et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 106, 804-808 (2002).
19. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 22, 788-792 (2002).
20. Chen M, Capps C, Willerson JT, Zoldhelyi P. E2F-1 regulates nuclear factor-κB activity and cell adhesion: potential antiinflammatory activity of the transcription factor E2F-1. Circulation 106, 2707-2713 (2002).
21. Damani SB, Topol EJ. Future use of genomics in coronary artery disease. J. Am. Coll. Cardiol. 50, 1933-1940 (2007).
22. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation MEF2A in an inherited disorder with features of coronary artery disease. Science 302, 1578-1581 (2003).
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 326, 242-250 (1992).
24. Davies MJ, Woolf N. Atherosclerosis: what is it and why does it occur? Br. Heart J. 69, S3-S11 (1993).
25. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1 Am. J. Pathol. 144, 952-961 (1994).
26. Libby P. Inflammation in atherosclerosis. Nature 420, 868-874 (2003).
27. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108, 1772-1778 (2002).
28. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108, 1664-1672 (2003).
29. Hyafil F, Cornily JC, Feig JE et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13, 636-641 (2007).
30. Kooi ME, Cappendijk VC, Cleutjens KB et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107, 2453-2458 (2003).
31. Tang T, Howarth SP, Miller SR et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 37, 2266-2270 (2006).
32. Trivedi RA, U-King-Im JM, Graves MJ et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35, 1631-1635 (2004).
33. Tang TY, Howarth SP, Miller SR et al. Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced MR imaging with degree of luminal stenosis. Stroke 39, 2144-2147 (2008).
34. Korosoglou G, Weiss RG, Kedziorek DA et al. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using "positive contrast" magnetic resonance imaging. J. Am. Coll. Cardiol. 52, 483-491 (2008).
35. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117, 379-387 (2008).
36. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 5, 85-92 (2006).
37. Virgolini I, Muller C, Fitscha P, Chiba P, Sinzinger H. Radiolabelling autologous monocytes with 111-indium-oxine for reinjection in patients with atherosclerosis. Prog. Clin. Biol. Res. 355, 271-280 (1990).
38. Lederman RJ, Raylman RR, Fisher SJ et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl. Med. Commun. 22, 747-753 (2001).
39. 18F-FDG PET/CT. J. Nucl. Med. 45, 1816-1821 (2004).
40. 18F-fluorodeoxyglucose positron emission tomography. Circulation 105, 2708-2711 (2002).
41. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48, 1818-1824 (2006).
42. Tahara N, Kai H, Nakaura H et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur. Heart J. 28, 2243-2248 (2007).
43. 18F-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J. Am. Coll. Cardiol. 49, 1533-1539 (2007).
44. Tahara N, Kai H, Ishibashi M et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48, 1825-1831 (2006).
45. Gawaz M, Neumann FJ, Dickfeld T et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 98, 1164-1171 (1998).
46. Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: an autoradiographic study. Circulation 104, 203-208 (2001).
47. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96, 327-336 (2005).
48. Nahrendorf M, Jaffer FA, Kelly KA et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114, 1504-1511 (2006).
49. Kaufmann BA, Sanders JM, Davis C et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116, 276-284 (2007).
50. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J. Nucl. Med. 46, 1186-1193 (2005).
51. Kolodgie FD, Petrov A, Virmani R et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108, 3134-3139 (2003).
52. Narula J, Acio ER, Narula N et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 7, 1347-1352 (2001).
53. Hofstra L, Liem IH, Dumont EA et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356, 209-212 (2000).
54. Isobe S, Tsimikas S, Zhou J et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J. Nucl. Med. 47, 1497-1505 (2006).
55. Lancelot E, Amirbekian V, Brigger I et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler. Thromb. Vasc. Biol. 28, 425-432 (2008).
56. Williams JK, Heistad DD. [The vasa vasorum of the arteries]. J. Mal. Vasc. 21 (Suppl. C), 266-269 (1996).
57. Risau W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
58. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003).
59. Isner JM. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation 99, 1653-1655 (1999).
60. Kwon HM, Sangiorgi G, Ritman EL et al. Enhanced coronary vasa vasoram neovascularization in experimental hypercholesterolemia. J. Clin. Invest. 101, 1551-1556 (1998).
61. Herrmann T, Lerman LO, Rodriguez-Porcel M et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc. Res. 51, 762-766 (2001).
62. Moreno PR, Purushothaman KR, Fuster V et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110, 2032-2038 (2004).
63. Lee KH, Jung KH, Song SH et al. Radiolabeled RGD uptake and α-V integrin expression is enhanced in ischemic murine hindlimbs. J. Nucl. Med. 46, 472-478 (2005).
64. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63, 5838-5843 (2003).
65. Leong-Poi H, Christiansen J, Heppner P et al. Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation 111, 3248-3254 (2005).
66. 99mTc-labeled peptide targeted at αvβ3 integrin after murine hindlimb ischemia. Circulation 111, 3255-3260 (2005).
67. Kerwin W, Hooker A, Spilker M et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 107, 851-856 (2003).
68. Turetschek K, Huber S, Floyd E et al. MR imaging characterization of microvessels in experimental breast tumors by using a paniculate contrast agent with histopathologic correlation. Radiology 218, 562-569 (2001).
69. Carlier S, Kakadiaris IA, Dib N et al. Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. Curr. Atheroscler. Rep. 7, 164-169 (2005).
70. Feinstein SB. The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am. J. Physiol. Heart Circ. Physiol. 287, H450-H457 (2004).
71. Cavanaugh D, Johnson E, Price RE, Kurie J, Travis EL, Cody DD. In vivo respiratory-gated micro-CT imaging in small-animal oncology models. Mol. Imaging 3, 55-62 (2004).
72. Dover SD, Elliott JC, Boakes R, Bowen DK. Three-dimensional x-ray microscopy with accurate registration of tomographic sections. J. Microsc. 153, 187-191 (1989).
73. Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M. The direct examination of three-dimensional bone architecture in vitro by computed tomography. J. Bone Miner. Res. 4, 3-11 (1989).
74. Flannery BP, Deckman HW, Roberge WG, D'Amico KL. Three-dimensional x-ray microtomography. Science 237, 1439-1444 (1987).
75. Haddad WS, McNulty I, Trebes JE, Anderson EH, Levesque RA, Yang L. Ultrahigh-resolution x-ray tomography. Science 266, 1213-1215 (1994).
76. Muller R, Van Campenhout H, Van Damme B et al. Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 23, 59-66 (1998).
77. Garcia-Sanz A, Rodriguez-Barbero A, Bentley MD, Ritman EL, Romero JC. Three-dimensional microcomputed tomography of renal vasculature in rats. Hypertension 31, 440-444 (1998).
78. Jorgensen SM, Demirkaya O, Ritman EL. Three-dimensional imaging of vascalature and parenchyma in intact rodent organs with x-ray micro-CT. Am. J. Physiol. 275, H1103-H1114 (1998).
79. Kantor B, Jorgensen SM, Lund PE, Chmelik MS, Reyes DA, Ritman EL. Cryostatic micro-computed tomography imaging of arterial wall perfusion. Scanning 24, 186-190 (2002).
80. -/- double knockout mice. Atherosclerosis 191, 73-81 (2007).
81. -/-) double knockout mice. Arterioscler. Thromb. Vasc. Biol. 26, 347-352 (2006).
82. Lerman A, Ritman EL. Evaluation of microvascular anatomy by micro-CT. Herz 24, 531-533 (1999).
83. Mohlenkamp S, Behrenbeck TR, Lerman A et al. Coronary microvascular functional reserve: quantification of long-term changes with electron-beam CT preliminary results in a porcine model. Radiology 221, 229-236 (2001).
84. Rodriguez-Porcel M, Lerman A, Ritman EL, Wilson SH, Best PJ, Lerman LO. Altered myocardial microvascular 3D architecture in experimental hypercholesterolemia. Circulation 102, 2028-2030 (2000).
85. Wan SY, Kiraly AP, Ritman EL, Higgins WE. Extraction of the hepatic vasculature in rats using 3-D micro-CT images. IEEE Trans. Med. Imaging 19, 964-971 (2000).
86. Wilson SH, Herrmann J, Lerman LO et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105, 415-418 (2002).
87. Zhu XY, Rodriguez-Porcel M, Bentley MD et al. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation 109, 2109-2115 (2004).
88. Langheinrich AC, Bohle RM, Greschus S et al. Atherosclerotic lesions at micro CT: feasibility for analysis of coronary artery wall in autopsy specimens. Radiology 231, 675-681 (2004).
89. Chen J, Tung CH, Mahmood U et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 105; 2766-2771 (2002).
90. Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev. Mol. Diagn. 3(2), 153-161 (2003).
91. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 8, 1112-1120 (2003).
92. Dunford R, Salinaro A, Cai L et al. Chemical oxidation and DNA damage catalysed by inorganic sunscreen ingredients. FEBS Lett. 418, 87-90 (1997).
93. Shvedova AA, Castranova V, Kisin ER et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J. Toxicol. Environ. Health A 66, 1909-1926 (2003).
94. Lam CW, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci. 77, 126-134 (2004).
95. Lam PK, Chin ES, Ho WS, Liew CT. In vitro cytotoxicity testing of a nanocrystalline silver dressing (Acticoat) on cultured keratinocytes. Br. J. Biomed. Sci. 61, 125-127 (2304).
96. Poon VK, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns 30, 140-147 (2004).